Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid‐β peptide

Recent data have revealed that soluble oligomeric forms of amyloid peptide (Aβ) may be the proximate effectors of the neuronal injury and death occurring in Alzheimer's disease (AD). However, the molecular mechanisms associated with the neuronal cell death induced by the nonfibrillar Aβ remain to be elucidated. In this study, we investigated the role of the cytosolic Ca2+‐dependent phospholipase A2 (cPLA2), and its associated metabolic pathway, i.e., the arachidonic acid (AA) cascade, in the apoptotic cell death induced by soluble oligomers of Aβ. The treatment of rat cortical neurons with low concentrations of soluble Aβ(1‐40) or Aβ(1‐42) peptide resulted in an early calcium‐dependent release of AA associated with a transient relocalization of cPLA2. Both cPLA2 antisense oligonucleotides and a selective inhibitor of cPLA2 activity abolished the release of AA from neurons and also protected cells against apoptosis induced by Aβ. Furthermore, inhibitors of the PKC, p38, and MEK/ERK pathways that are involved in cPLA2 phosphorylation and activation reduced Aβ‐induced cell death. Finally, we demonstrate that inhibitors of cyclooxygenase‐2 reduced the Aβ‐induced cell death by 55%. Our studies suggest a novel neuronal response of soluble oligomers of Aβ, which occurs through a cPLA2 signaling cascade and an AA‐dependent death pathway. This may prove to be crucial in AD processes and could provide important targets for drug development.

[1]  E. Rogaev,et al.  Molecular basis of Alzheimer’s disease , 2007, Molecular Biology.

[2]  Á. Simonyi,et al.  Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. , 2004, Journal of lipid research.

[3]  C. Leslie,et al.  The calcium binding loops of the cytosolic phospholipase A2 C2 domain specify targeting to Golgi and ER in live cells. , 2003, Molecular biology of the cell.

[4]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[5]  I. Sponne,et al.  Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid-β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation* , 2003, The Journal of Biological Chemistry.

[6]  W. Klein,et al.  Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[8]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[9]  C. Leslie,et al.  Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA2 phosphorylation and translocation , 2002, BMC Biochemistry.

[10]  T. Pillot,et al.  The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. , 2002, Journal of neurochemistry.

[11]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[12]  Q. Fan,et al.  A Novel Action of Alzheimer's Amyloid β-Protein (Aβ): Oligomeric Aβ Promotes Lipid Release , 2001, The Journal of Neuroscience.

[13]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[14]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[15]  N. Nishiyama,et al.  Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability , 2001, The European journal of neuroscience.

[16]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[17]  P. Cohen,et al.  Serine 727 Phosphorylation and Activation of Cytosolic Phospholipase A2 by MNK1-related Protein Kinases* , 2000, The Journal of Biological Chemistry.

[18]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[19]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[20]  G. Béréziat,et al.  N-terminal and C-terminal plasma membrane anchoring modulate differently agonist-induced activation of cytosolic phospholipase A2. , 1999, European journal of biochemistry.

[21]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[22]  D. Stephenson,et al.  Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration , 1999, Glia.

[23]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Estus,et al.  Aggregated Amyloid-β Protein Induces Cortical Neuronal Apoptosis and Concomitant “Apoptotic” Pattern of Gene Induction , 1997, The Journal of Neuroscience.

[26]  C. Leslie Properties and Regulation of Cytosolic Phospholipase A2 * , 1997, The Journal of Biological Chemistry.

[27]  L. Horrocks,et al.  Involvement of phospholipase A2 in neurodegeneration , 1997, Neurochemistry International.

[28]  M. Cathcart,et al.  Selective Inhibition of Cytosolic Phospholipase A2 in Activated Human Monocytes , 1997, The Journal of Biological Chemistry.

[29]  D. Stephenson,et al.  Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. , 1996, Journal of lipid mediators and cell signalling.

[30]  C. Cotman,et al.  DNA damage and apoptosis in Alzheimer's disease: colocalization with c- Jun immunoreactivity, relationship to brain area, and effect of postmortem delay , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[32]  William L. Smith,et al.  Calcium-mediated Translocation of Cytosolic Phospholipase A2 to the Nuclear Envelope and Endoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.

[33]  S. Rapoport,et al.  Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain , 1995, Brain Research.

[34]  L. Horrocks,et al.  Neural membrane phospholipids in alzheimer disease , 1995, Neurochemical Research.

[35]  D. Piomelli,et al.  Dopamine D2 Receptors Potentiate Arachidonate Release via Activation of Cytosolic, Arachidonate‐Specific Phospholipase A2 , 1995, Journal of neurochemistry.

[36]  J. Pettegrew,et al.  Alzheimer's Disease: Membrane‐Associated Metabolic Changes a , 1994, Annals of the New York Academy of Sciences.

[37]  T. Molski,et al.  Cytoplasmic phospholipase A2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. V. Hogan,et al.  Long-term potentiation in the hippocampus induced by platelet-activating factor , 1993, Neuron.

[39]  Roger J. Davis,et al.  cPLA2 is phosphorylated and activated by MAP kinase , 1993, Cell.

[40]  J. D. Clark,et al.  A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP , 1991, Cell.

[41]  C. Leslie,et al.  A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. , 1990, The Journal of biological chemistry.

[42]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[43]  L. Horrocks,et al.  Elevated Activities of Lipases and Lysophospholipase in Alzheimer's Disease , 1990 .